Compare SRPT & NOMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | NOMD |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2000 | 2015 |
| Metric | SRPT | NOMD |
|---|---|---|
| Price | $15.58 | $12.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 4 |
| Target Price | ★ $25.85 | $12.50 |
| AVG Volume (30 Days) | ★ 3.0M | 1.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 7.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.45 |
| P/E Ratio | ★ $5.35 | $8.38 |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $14.68 | $8.99 |
| 52 Week High | $25.32 | $17.30 |
| Indicator | SRPT | NOMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 75.26 |
| Support Level | N/A | $12.48 |
| Resistance Level | $18.16 | $13.04 |
| Average True Range (ATR) | 0.88 | 0.36 |
| MACD | -0.30 | 0.03 |
| Stochastic Oscillator | 4.46 | 94.41 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.